AP
EW icon

Arlington Partners’s Edwards Lifesciences EW Stock Holding History

Arlington Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,445
Closed -$110K – 119
2023
Q4 		$110K Buy
1,445
+1,208
+510% +$84.1K 0.03% 101
2023
Q3 		$16.4K Sell
237
-362
-60% -$29.1K 0.01% 198
2023
Q2 		$56.5K Buy
599
+362
+153% +$31.5K 0.01% 293
2023
Q1 		$19.6K Buy
237
+24
+11% +$1.89K ﹤0.01% 345
2022
Q4 		$15.9K Hold
213
– – ﹤0.01% 329
2022
Q3 		$18K Hold
213
– – 0.01% 268
2022
Q2 		$20K Hold
213
– – 0.01% 325
2022
Q1 		$25K Sell
213
-51
-19% -$5.72K 0.01% 310
2021
Q4 		$34K Buy
+264
New +$30.8K 0.01% 317
2020
Q2 		– Sell
-6
Closed – – 208
2020
Q1 		$0 Buy
+6
New +$433 ﹤0.01% 326

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Arlington Partners's EW Position: Q1 2024 in Review

Arlington Partners sold out of Edwards Lifesciences (EW) in Q1 2024, closing a stake of 1,445 shares — an estimated $110K sold.

Arlington Partners first reported a position in EW in Q1 2020 and held it in 10 quarters. The position peaked at $110K in Q4 2023. 1,281 funds tracked by Wall St. Rank hold EW as of Q1 2024.

  • Arlington Partners reported no remaining Edwards Lifesciences position as of Q1 2024 after selling out during the quarter.
  • Arlington Partners sold 1,445 Edwards Lifesciences shares in Q1 2024, an estimated $110K.
  • Arlington Partners first reported a position in Edwards Lifesciences in Q1 2020 and held it in 10 quarters.
  • Arlington Partners's Edwards Lifesciences position peaked at $110K in Q4 2023.
  • 1,281 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2024.

Based on Arlington Partners's 13F filing for Q1 2024, filed 16 Apr 2024.